New pill could ease severe eczema in major trial
NCT ID NCT07370909
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 study tests an oral tablet called LW402 in 480 adults with moderate-to-severe atopic dermatitis (eczema). Participants will take either the drug or a placebo daily for 16 weeks. The goal is to see if LW402 can significantly improve eczema severity and skin clearance compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LW402 tablets
- What this could lead to
- If it works, this could provide a new oral treatment option to reduce eczema severity and improve skin appearance for people with moderate-to-severe atopic dermatitis.
- What could go wrong
- This is a phase 3 trial, but results are not yet available. The drug may not work better than placebo, and side effects are possible. It is not a cure and ongoing treatment may be needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill tame tough eczema? a large trial aims to find out
- New shot could tame tough eczema by calming overactive immune cells
- New drug aims to calm severe eczema without steroids
- New drug shows promise for severe eczema in toddlers
- Eczema drug nemolizumab put to the vaccine test
- New shot could tame severe eczema in kids